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Abstract: Unaffordable prices still bar the end-users in China from accessing ARV drugs. Patent protection of ARV 
drugs has dramatically limited the availability of these lifesaving drugs to AIDS patients in China. 
The way Chinese government can go to breakthrough the ARV drug patents are suggested as: 
-  Make more generic drugs available through compulsory licensing, impartment from other countries or building 
ARVs plants by partnerships between governments or generic drug companies. 
-  Do a thorough and detailed research on the patent application of ARV drugs to find out the loophole. 
-  Try patent pool to make AIDS medicines more affordable and appropriate for patients. 
INTRODUCTION 
  China, a vast country of 1.3 billion people, faces 
tremendous logistical challenges in combating the 
HIV/AIDS epidemic. The most recent statistics released by 
the Chinese government in December 2008 showed that the 
number of HIV-infected individuals reported was about 
260,000 and the number of full-blown AIDS patients was 
more than 77,000 at the end of September 2008. In China, 
the government has recognized the imminent threat that 
HIV/AIDS poses to its population and responded with a 
national antiretroviral (ARV) treatment program providing 
ARV drugs free to those most in need [1]. It has been five 
years since the national free ARV therapy was put into effect 
in 2003. Generally speaking, this urgent and helpful action 
was quite meaningful to the promotion and extension of the 
China’s AIDS prevention and control project [2]. Nearly 
RMB25,000 (about US$3571) for one patient’s yearly 
treatment, the improved first-line treatment (Zidovudine 
(AZT) or Stavudine (D4T) + lamivudine(3TC) + efavirenz 
(EFV)) in China costs five to eight times as much as the 
previously recommended regimen. With increasing numbers 
of AIDS patients failing on their first-line therapy, there is 
also an urgent need to find affordable second-line treatments. 
But only twelve of the more than 30 kinds of ARV drugs are 
available in the country and seven of them need to be 
imported because of protection of drug patents. And now the 
prices of AIDS medicines are still on the rise. As a result, 
unaffordable prices still bar the end-users in China from 
accessing these lifesaving drugs. Under this backcloth, 
prospects from production generic ARV drugs, compulsory  
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licensing and patent pool show that China still has a long 
way to go in ensuring access of necessary ARV drugs for 
AIDS patient. 
HIV EPIDEMIC AND ARV PATENT IN CHINA 
  Since 1985, the HIV epidemic has become more visible 
in China. The cases reported are increasing every year and 
have spread throughout the country [3]. Despite new HIV 
infections are increasing at a much slower pace (Fig. 1), 
WHO warned that, if there were no effective preventive 
measures adopted, that the number of HIV/AIDS cases 
would reach 10 million in China by 2010 [4], and the 
number of AIDS patient would be about 1,097,000 to 
2,155,000. According to the report released by the National 
Center for AIDS and Sexually Transmitted Disease Control 
and Prevention, HIV/AIDS has begun to spread from 
specific groups into the general population and many risk 
factors of HIV transmission remain uncontrolled. In the 
recent years, unprotected sex is gradually becoming a major 
route of transmission for HIV/AIDS epidemic in China, and 
with increases in the number of female HIV patients infected 
through sex, mother-to-child transmission is bound to 
increase. The percentage of unprotected sex between men 
and women reached 40.4% and that of unprotected sex 
between men was about 5.1% in 2008. At the present time, 
the HIV epidemic still presents a huge challenge for 
developing China in areas of awareness, financial support, 
staffing, prevention, treatment and care. 
  The treatment of HIV/AIDS that has advanced 
tremendously over the past two decades decreased the AIDS 
mortality rate and many patients may now be able to live a 
normal life. Thirty-two drugs have been authorized by FDA 
for the HIV/AIDS therapy and can be categorized into six 
kinds, namely nucleoside reverse transcriptase inhibitors, 
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inhibitors, Fusion inhibitors, entry inhibitors - CCR5 co-
receptor antagonist, HIV integrase strand transfer inhibitors 
and Multi-class Combination Products [5] (Table 1). Most of 
these drugs are expensive because of patent protection and 
it’s a big problem for poor and resource-limited countries 
such as China. Over the past decade activist pressure, the 
emergence of competition from generic manufacturers, and 
direct negotiation with pharmaceutical companies have all 
contributed to a dramatic drop in the price of certain drugs in 
developing countries. The availability of cheap antiretroviral 
drugs has been instrumental in treatment scale-up for 
resource-poor settings hard hit by the AIDS epidemic. 
Despite significant advances, a number of problems related 
to the price of anti-AIDS drugs remain. Not all drugs to treat 
AIDS are available at a suitably cheap price for poor 
countries, meaning that many of the newer, more effective 
drugs are only available in the West. 
  Although the challenges facing HIV/AIDS control in 
China are many, the Chinese government is making a strong 
commitment to implement effective AIDS control measures 
across the whole country [6,7]. Since early 21st century, the 
Chinese government has vigorously responded to the 
HIV/AIDS epidemic and announced the “China Care 
Project”, a new policy for comprehensive HIV/AIDS 
prevention and treatment. A major accomplishment in 
prevention and treatment came in 2003, with the 
establishment of the “Four Frees and One Care” policy [8]. 
The government has provided free ARV treatment to 58,000 
AIDS patients since then. Thanks to the treatment, the 
mortality rate among AIDS patients dropped from 28.7 
percent in 2002 to 5.8 percent in 2007, according to a survey 
of the National Center for AIDS and Sexually Transmitted 
Disease Control and Prevention. In recent years the Central 
Government financial input to AIDS prevention and care has 
been significantly increased. Central government resources 
devoted to AIDS was RMB 15 million (about $ 2.1 million) 
in the middle of 90's of 20th century, which increased to 944 
million (about $135 million)in 2007. In accordance with the 
incomplete data from local AIDS Working Committee 
Office, local financial commitments showed a corresponding 
increase. China is in urgent need of low-cost, less-side 
effects, and eutherapeutic ARV drugs. With the coordination 
and joint efforts by State Council AIDS Working Committee 
Office (SCAWCO), the Ministry of Finance, the State 
Administration of Taxation, the National Development & 
Reform Commission and the General Administration of 
Customs, the State Council was maintaining customs 
exemption for the import of ARV drugs and approving tax 
exemptions for the local production of ARV drugs in 2007. 
The exemption helped stabilize the price of ARV drugs and 
the price of some drugs decreased. As the number of 
pediatric cases increased, some pediatric drugs have been 
included in the plan for domestic production [9]. The 
government has been urging the patent owners or 
pharmaceutical companies under the administrative 
protection to localized their drug production and thereby to 
lower the price of ARV drugs. The government also has 
been persuading brand companies to give up their patent 
rights in China and help the Chinese government to provide 
effective treatment for AIDS patients [10]. 
  Being a large developing country, China has provided 
patent protection for new drugs since 1993. Most ARV drugs 
have patent protection in China. The price of most ARV 
drugs is beyond the affordability of AIDS patients. 
Nevertheless, China's current ARV choices are severely 
limited due to patent restrictions and many large 
pharmaceutical companies (known as ‘Big Pharma’) already 
registered their products in China but have not sale of these 
drugs in China such as lamivudine (3TC), Trizivir(Zidovu-
dine, AZT +ABC+3TC), abacavir (ABC) and saquinavir 
(SQV). Only twelve of thirty-two ARV drugs are available 
in China including five kinds of generic drugs (didanosine 
DDI, stavudin D4T, AZT, nevirapine NVP, and indinavir 
 
 
Fig. (1). HIV/AIDS individual reported in China from 1985 to September 2008 (Divisions of Treatment and Care, National Center for 
STD/AIDS Prevention and Control, Chinese Center for Disease Prevention and Control, Beijing). 
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Table 1.  Drugs Used in the Treatment of HIV Infection [5] 
 
Brand Name   Generic Name   Manufacturer Name   Approval Date  
A 
Combivir
*  lamivudine and zidovudine  GlaxoSmithKline  27-Sep-97 
Emtriva  emtricitabine, FTC   Gilead Sciences  02-Jul-03 
Epivir
*# lamivudine,  3TC  GlaxoSmithKline  17-Nov-95 
Epzicom abacavir  and  lamivudine  GlaxoSmithKline  02-Aug-04 
Hivid  zalcitabine, dideoxycytidine, ddC   Hoffmann-La Roche  19-Jun-92 
Retrovir
*#  zidovudine, azidothymidine, AZT, ZDV  GlaxoSmithKline  19-Mar-87 
Trizivir  abacavir, zidovudine, and lamivudine  GlaxoSmithKline  14-Nov-00 
Truvada  tenofovir disoproxil fumarate and emtricitabine  Gilead Sciences, Inc.  02-Aug-04 
Videx EC  enteric coated didanosine, ddI EC   Bristol Myers-Squibb  31-Oct-00 
Videx
*#  didanosine, dideoxyinosine, ddI  Bristol Myers-Squibb  9-Oct-91 
Viread
*  tenofovir disoproxil fumarate, TDF   Gilead  26-Oct-01 
Zerit
*  stavudine, d4T  Bristol Myers-Squibb  24-Jun-94 
Ziagen  abacavir sulfate, ABC   GlaxoSmithKline  17-Dec-98 
(generic version)   Didanosine (ddI)Delayed Release capsules   Barr Lab.   3-Dec-04  
B  
Intelence   etravirine   Tibotec Therapeutics  18-Jan-08 
Rescriptor delavirdine,  DLV  Pfizer  4-Apr-97 
Sustiva
*#  efavirenz, EFV   Bristol Myers-Squibb  17-Sep-98 
Viramune
*#  nevirapine, NVP   Boehringer Ingelheim  21-Jun-96 
C 
Agenerase amprenavir,  APV  GlaxoSmithKline  15-Apr-99 
Aptivus  tipranavir, TPV   Boehringer Ingelheim   22-Jun-05 
Crixivan
*#  indinavir, IDV,   Merck  13-Mar-96 
Fortovase  saquinavir (no longer marketed)   Hoffmann-La Roche  7-Nov-97 
Invirase  saquinavir mesylate, SQV  Hoffmann-La Roche  6-Dec-95 
Kaletra
*#  lopinavir and ritonavir, LPV/RTV  Abbott Laboratories  15-Sep-00 
Lexiva  Fosamprenavir Calcium, FOS-APV   GlaxoSmithKline  20-Oct-03 
Norvir  ritonavir, RTV   Abbott Laboratories  1-Mar-96 
Prezista darunavir  Tibotec,  Inc.  23-Jun-06 
Reyataz
*  atazanavir sulfate, ATV   Bristol-Myers Squibb  20-Jun-03 
Viracept
*  nelfinavir mesylate, NFV  Agouron Pharmaceuticals  14-Mar-97 
D 
Fuzeon  enfuvirtide, T-20  Hoffmann-La Roche & Trimeris  13-Mar-03 
E 
Selzentry maraviroc    Pfizer  06-August-07 
F 
Isentress  raltegravir   Merck & Co., Inc.  12--Oct-07 
G 
Atripla  efavirenz, emtricitabine and tenofovir disoproxil fumarate  Bristol-Myers Squibb and Gilead Sciences  12-July-06 
(A) Nucleoside reverse transcriptase inhibitors (NRTIs); (B) Nonnucleoside reverse transcriptase inhibitors (NNRTIs); (C) Protease inhibitors (PIs); (D) Fusion inhibitors; (E) Entry 
Inhibitors - CCR5 co-receptor antagonist;(F) HIV integrase strand transfer inhibitors;(G) Multi-class Combination Products. 
*Available in Chinese market 
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IDV). The free ARV drugs listed in “For Frees and One 
Care” policy include five generic drugs and 3TC, efavirenz 
(EFV), Kaletra (lopinavir and ritonavir, LPV/RTV) and 
tenofovir (TDF). Kaletra and TDF are second-line drugs and 
only patients with confirmed resistance to first-line drugs can 
switch to them. The Ministry of Health imported other 
drugs(3TC, EFV, Kaletra and TDF) from Brand companies. 
The cost of ARV drugs per patient per year was as high as 
RMB 30,000(about $4,225) to 50,000(about $7,143) before 
August 2002 when first generic drugs came into Chinese 
market. There are four pharmaceutical manufacturers 
involved in the production of the national free ARV drugs, 
including five kinds of generic drugs (DDI, D4T, AZT, 
NVP, and IDV) in China. The price of these drugs is only 
one-tenth of that imported drugs and some drugs are even 
cheaper. The price of D4T capsule (20mg) capsule produced 
by a pharmaceutical manufacturer in Shanghai is only RMB 
0.9 (about $0.13), but that of imported D4T (20mg, Zerit, 
Bristol Myers-Squibb) is as high as RMB 22.7 (about $3.24). 
These cheap generic ARV drugs make up a large number of 
first line drugs and have dramatically reduced the cost of 
antiretroviral therapy (ART) in China. The cost of ART has 
reduced dramatically after generic drugs came into Chinese 
market. This cost may be cut down to RMB3,000 (about 
$422.5) per year for one patient after localization of all the 
ARV drugs and the market space will more than RMB 30 
billion(about $4 billion). There are still difficulties in 
obtaining supplies of second-line ART drugs because the 
high price of ARV drugs. So the physicians still have not so 
much choice when they determine the ART regimen. 
GENERIC DRUGS AND COMPULSORY LICENSING 
IN CHINA 
  In order for the proprietary drug makers to recoup the 
money they spent on drug creation, brand company are 
granted a ‘patent’ (an intellectual property right), which is an 
exclusive right that prevents others from making, using, 
selling, offering to sell, or importing their drug. The patent 
typically lasts for twenty years. 3TC (300mg, Epivir, 
GlaxoSmithKline) is the most important drug in the first line 
and second line regimen in China. GlaxoSmithKline has the 
patent of 3TC and Combivir (3TC+AZT), and there is only 
Combivir in Chinese market and price is as high as RMB 
1300(about $186). Negotiation with GlaxoSmithKline has 
reduced the price of 3TC dramatically but this dosage form 
completely depends on government procurement because the 
dosage form in Chinese market is Heptode (100mg) treating 
hepatitis B. The company recently announced that the 
production of Combivir would be localization in China. It 
meant that the application of production of generic 3TC from 
Chinese government had been rejected. The government still 
has to spend a large amount of money in importing this drug. 
Generic 3TC is available in many developing country such 
as India. But no one knows when generic 3TC will appear in 
China. 
  Legislation in favor of the pharmaceutical industries’ 
right to patent their drugs - TRIPS - was introduced in 1995. 
TRIPS - The Agreement on Trade Related Aspects of 
Intellectual Property Rights –introduced intellectual property 
law into the international trading system for the first time 
and applies to all members of the World Trade Organization 
(WTO). The implementation of TRIPS was to have a huge 
impact on generic drug production. As a result, newer drugs 
are under patent and unaffordable prices still prevent in the 
resource-poor countries such as China from accessing these 
lifesaving drugs. Legally a country can get around TRIPS 
patent enforcement by issuing a compulsory license. A 
compulsory license is a government license that enables 
someone other than the patent holder to copy patented 
products and processes without fear of prosecution. 
Governments can issue them if a patent owner abuses their 
rights by, for example, failing to offer their product in the 
market, or offering it at a price that is too high for potential 
buyers to afford. Normally, to copy drugs for this reason, the 
generic company has to negotiate with the original 
manufacturer to agree royalties (money paid to the patent 
holder to make up for the loss of profit exclusivity). 
However, following the 2001 Doha agreement a country can 
issue a compulsory licence for a drug that treats a disease 
causing a severe health emergency in that country without 
royalties being paid [11]. Despite endorsement by the WTO, 
because of its complicated nature, compulsory licensing has 
been used very little by low- and middle-income countries. 
In fact, to date only a few country such as Thailand and 
Brazil have issued a compulsory licence for an antiretroviral 
drug and provides an excellent example of why other 
countries have been reluctant to follow suit [12]. It was once 
said that Chinese government would use compulsory licence, 
but it was proved to be a hearsay at last. Some people 
believe that it is can not be regarded as a public health 
emergency with the number of HIV-infected individuals 
reported in China. In fact, it is a misunderstanding of TRIPS. 
AIDS is regarded as a public health emergency in Doha 
agreement and there is no definition of the number or 
proportion of AIDS patients. Chinese government can 
consider compulsory licence just in order to provide 
necessary drug for AIDS patiens. Or it can serve as a 
bargaining chip when the government negotiates with brand 
pharmaceutical manufacturers. 
  China currently produces first-line ARV drugs along with 
the active pharmaceutical ingredients (APIs) for second lines 
too: really, China could become the ARV factory for the 
poor world because of its cheapest APIs and industrial 
scaleup very interested in the under-served markets. 
Unequivocal choices are lacking, however, between 
pursuance of TRIPS flexibilities of WTO (which China 
belongs to) and huge business with the multinational giants 
(including direct price cuttings for brand ARV drugs) [13]. 
The government should do a thorough and detailed research 
on the patent application of ARV drugs to find out the 
breakthrough. Although the production method of 3TC is 
still in the patent protection, the new drug protection and 
administrative protection of 3TC already expired.  It is 
invalid that GlaxoSmithKline assert their patent of 
production method of 3TC have the faction of product patent 
of this drug, because the company abused patent rights and 
expanded monopoly. Or the government can use compulsory 
licensing and authorize production of generic 3TC. 58    The Open AIDS Journal, 2010, Volume 4  Liu and Lu 
  The World Trade Organization (WTO) issued the so-
called ‘paragraph 6 waiver’ which allows members who are 
unable to produce pharmaceuticals at home and are suffering 
a serious health crisis to import generics from other nations 
under compulsory licences (providing exported drugs are not 
part of a commercial or industrial policy of the exporting 
country) [14]. Many developing country have been trying 
their best to provide cheap pharmaceuticals for people 
suffering from AIDS. India is the largest supplier of generic 
ARV drugs to low- and middle- income countries, exporting 
two thirds of the drugs it manufactures [15]. Brazil, Thailand 
and South Africa also produce a significant amount of 
generic drugs and have used their expertise to help a number 
of African nations - such as Zambia, Ghana, Tanzania, 
Uganda, Ethiopia and Zimbabwe - develop local AIDS drug 
manufacturing facilities [16]. The manufacture and export of 
generic drugs was not only a turning point in terms of the 
price of ARV drugs, but also helped to revolutionize 
treatment for resource-poor settings by simplifying HIV/ 
AIDS treatment. In 2001, Indian generic drug manufacturer, 
Cipla, announced that it would sell a generic copy of a triple-
therapy antiretroviral for US$350 per patient per year. This 
had an incredible impact as the competition this generated 
dramatically drove down the price of anti-AIDS drugs for 
developing countries, thereby increasing the range of 
affordable options for national treatment programmers. To 
date, the Chinese government has snobbed the Indian ARV 
drugs even though they are cheapest through the Clinton 
Foundation, a consortium which China is a member of. How 
much longer will it be worthwhile to Chinese government 
ignoring the saving money opportunities by Indian generics? 
Not for long, if China-India trade agreements of November 
2006 and January 2008 are supposed to give rise to a 
mutually profitable partnership for ARV drugs manufactu-
ring and marketing [13]. 
PATENT POOL 
  In 2008, the international drug purchasing agency 
UNITAID took the groundbreaking decision to pursue the 
idea of establishing a patent pool that could hold the key to 
future access to affordable newer medicines. A patent pool is 
a mechanism whereby patent owners agree to pull their 
patents and license them to one entity called a Patent Pool. 
As a result, any company who would like to use an invention 
within the patent pool can do so provided that it pays a 
royalty fee to the Pool. Patent pools as a tool for the 
collective management of intellectual property rights are not 
a new concept. The potential use of patent pools in the 
pharmaceutical industry has been raised by the World Health 
Organisation (WHO) as a possible solution to promoting 
better access to medicines in developing countries. 
Specifically for AIDS, the pool would hold licences on 
various patented medicines, which generic companies could 
then produce at a lower cost for poor countries [12] 
Although the creation of a patent pool for HIV/AIDS drugs 
is at an early stage, there is hope that it will make the 
production of generic versions of antiretrovirals easier to 
negotiate and therefore faster and more efficient. A patent 
pool could help make AIDS medicines more affordable and 
appropriate for patients. For example, it could facilitate the 
development of fixed-dose combinations of first- and 
second-line regimens for adults and children. By combining 
multiple drugs into one pill, treatment is easier to take for 
patients, which can enhance patient adherence, improve 
health outcomes, and reduce the risk of resistance. The next 
steps undertaken by UNITAID will be to set up a task force 
to develop an operational plan for the creation of a patent 
pool. It is a good news for most developing countries 
including China. The  pool will be  voluntary. So the plan 
stands or falls on the willingness of the patent holders to put 
their intellectual property in the pool and for others to make 
use of the patents, in exchange for royalties [17]. For the 
large under-served market in China, a patent pool could 
become a win-win strategy for the government and brand 
companies. 
THE WAY FORWARD FOR CHINA 
  Any such radical changes to the current system are 
unlikely any time soon, leaving it up to governments, drugs 
manufacturers, campaigners and non-governmental organi-
zations to force the price of AIDS drugs down, enabling 
health authorities to secure the drugs their people so despe-
rately need. 
  The way Chinese government can try to breakthrough the 
ARV drug patents are suggested as: 
-  Make more generic drugs available through compul-
sory licensing, impartment from other countries or 
building ARVs plants by partnerships between gover-
nments or generic drug companies. 
-  Do a thorough and detailed research on the patent 
application of ARV drugs to find out the loophole. 
-  Try patent pool to make AIDS medicines more 
affordable and appropriate for patients. 
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